11:56 AM EDT, 06/11/2024 (MT Newswires) -- Tiziana Life Sciences ( TLSA ) said Tuesday that it has received acceptance of its submission for intranasal foralumab to get Fast Track Designation approval for the treatment of non-active, secondary-progressive multiple sclerosis to the US Food and Drug Administration.

Foralumab is a biological drug candidate shown to cause T regulatory cell induction when dosed intranasally, the firm said.

A drug with the label is eligible for some benefits, including more frequent meetings with the FDA to discuss its development plan and ensure collection of appropriate data needed to support drug approval.

The stock was down more than 6% in recent trading.

Price: 0.92, Change: -0.06, Percent Change: -6.02